Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.

Mattsson N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131. Review.

PMID:
20201744
2.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
3.

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.

Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K.

Alzheimers Dement. 2011 Jul;7(4):386-395.e6. doi: 10.1016/j.jalz.2011.05.2243. Erratum in: Alzheimers Dement. 2011 Sep;7(5):556.

4.

CSF biomarker variability in the Alzheimer's Association quality control program.

Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Kaeser SA, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K; Alzheimer's Association QC Program Work Group..

Alzheimers Dement. 2013 May;9(3):251-61. doi: 10.1016/j.jalz.2013.01.010. Erratum in: Alzheimers Dement. 2015 Feb;11(2):237. Käser, Stephan A [corrected to Kaeser, Stephan A]; Rissman, Robert [corrected to Rissman, Robert A].

5.

Cerebrospinal fluid biomarkers for Alzheimer's disease: current limitations and recent developments.

Zetterberg H.

Curr Opin Psychiatry. 2015 Sep;28(5):402-9. doi: 10.1097/YCO.0000000000000179. Review.

PMID:
26147615
6.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
7.

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.

Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A.

Clin Chim Acta. 2015 Sep 20;449:9-15. doi: 10.1016/j.cca.2015.05.024. Epub 2015 Jun 30. Review.

PMID:
26141614
8.

Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.

Höglund K, Fourier A, Perret-Liaudet A, Zetterberg H, Blennow K, Portelius E.

Clin Chim Acta. 2015 Sep 20;449:3-8. doi: 10.1016/j.cca.2015.01.041. Epub 2015 Feb 7. Review.

PMID:
25668231
9.

CSF biomarkers for Alzheimer's disease: current utility and potential future use.

Holtzman DM.

Neurobiol Aging. 2011 Dec;32 Suppl 1:S4-9. doi: 10.1016/j.neurobiolaging.2011.09.003.

10.

Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau.

Li G, Xiong K, Korff A, Pan C, Quinn JF, Galasko DR, Liu C, Montine TJ, Peskind ER, Zhang J.

J Alzheimers Dis. 2015;47(4):883-7. doi: 10.3233/JAD-150420.

PMID:
26401768
11.

International quality control survey of neurochemical dementia diagnostics.

Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, Petereit HF, Tumani H, Gerritzen A, Oschmann P, Schröder J, Schönknecht P, Zimmermann K, Hampel H, Bürger K, Otto M, Haustein S, Herzog K, Dannenberg R, Wurster U, Bibl M, Maler JM, Reubach U, Kornhuber J, Wiltfang J.

Neurosci Lett. 2006 Nov 27;409(1):1-4. Epub 2006 Oct 11.

PMID:
17045397
12.

Cerebrospinal fluid biomarkers for Alzheimer's disease.

Blennow K, Zetterberg H.

J Alzheimers Dis. 2009;18(2):413-7. doi: 10.3233/JAD-2009-1177. Review.

PMID:
19661632
13.

The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Engelborghs S, Le Bastard N.

Mol Diagn Ther. 2012 Jun 1;16(3):135-41. doi: 10.2165/11634170-000000000-00000.

PMID:
22646065
14.

Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.

Huded CB, Bharath S, Chandra SR, Sivakumar PT, Varghese M, Subramanian S.

Asian J Psychiatr. 2015 Feb;13:44-7. doi: 10.1016/j.ajp.2014.10.007. Epub 2014 Nov 6.

PMID:
25468261
15.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21. Review.

16.

Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study.

Shea YF, Chu LW, Zhou L, Li WM, Lin OY, Chan MN, Xu A, Wong R, Ho TY, Liu KW, Ha J, Daniel TW, Song YQ, Lam KS.

Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):769-75. doi: 10.1177/1533317513504615. Epub 2013 Oct 1.

PMID:
24085246
17.

Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration.

Petzold A, Verwey NA, van Uffelen K, Blankenstein MA, Teunissen C.

J Neurosci Methods. 2010 Nov 30;193(2):296-9. doi: 10.1016/j.jneumeth.2010.08.028. Epub 2010 Sep 9.

PMID:
20832428
18.

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.

Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K.

Biomark Med. 2012 Aug;6(4):401-7. doi: 10.2217/bmm.12.41. Review.

PMID:
22917142
19.

Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.

Savage MJ, Holder DJ, Wu G, Kaplow J, Siuciak JA, Potter WZ; Foundation for National Institutes of Health (FNIH) Biomarkers Consortium CSF Proteomics Project Team for Alzheimer's Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;46(2):431-40. doi: 10.3233/JAD-142778.

PMID:
25790831
20.

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K.

Acta Neurol Scand Suppl. 2003;179:47-51.

PMID:
12603251

Supplemental Content

Support Center